您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MX69
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MX69
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1005264-47-0
规格:≥98%
包装与价格:
包装价格(元)
1mg电议
2mg电议
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)474.57
FormulaC27H26N2O4S
CAS No.1005264-47-0
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 95 mg/mL (200.2 mM)
Water: <1 mg/mL
Ethanol: 41 mg/mL (86.4 mM)
SMILES Code O=S(C1=CC2=C(NC(C3=CC=C(C(O)=O)C=C3)C4C2C=CC4)C=C1)(NC5=C(C)C(C)=CC=C5)=O
Synonyms MX69; MX-69; MX 69
实验参考方法
In Vitro

In vitro activity: MX69 is a novel, potent and selective MDM2/XIAP dual inhibitor that has the potential use for treatment of cancer. MX69 blocks the MDM2 protein-XIAP RNA interaction which leads to MDM2 degradation. MX69 shows minimal inhibitory effect on normal human hematopoiesis in vitro and is very well tolerated in animal models. MX69-induced MDM2 downregulation results not only in inhibition of XIAP expression, but also in activation of p53, which contributes to cancer cell apoptosis in vitro and inhibition of cancer cell proliferation in vivo. The compound-induced MDM2 downregulation resulted not only in inhibition of XIAP expression, but also in activation of p53, which contributed to cancer cell apoptosis in vitro and inhibition of cancer cell proliferation in vivo. Importantly, one of the MDM2/XIAP inhibitors, MX69, showed minimal inhibitory effect on normal human hematopoiesis in vitro and was very well tolerated in animal models. MX69 inhibits expression of both MDM2 and XIAP in a time- and dose-dependent manner. MX69 induces ubiquitination of endogenous MDM2 in cancer cells. Downregulation of MDM2 by MX69 is through induction of MDM2 self-ubiquitination and degradation. Half-life of MDM2 in control-treated EU-1 cells is greater than 90 min, whereas MX69 treatment decreases the MDM2 half-life to<30 min. In SK-N-SH cells with stably transfected either wild-type (WT)-MDM2 or mutant MDM2-C464A, Treatment with MX69 significantly inhibits expression and increased the turnover of WT-MDM2 but not MDM2-C464A. MX69 significantly enhances the p53 half-life in WT-MDM2 but not mutant MDM2-C464A-transfected SK-N-SH cells. p53 is stabilized and accumulates in MX69-treated cells. MX69-mediated inhibition of XIAP is MDM2 dependent. Treatment of MX69 activates caspases 3, 7, and 9 as well as the cleavage of the death substrate PARP. MX69 also exhibits a significant cytotoxic effect on both ALL and NB lines(cancer cell lines), particularly those lines with MDM2 overexpression and a WTp53 phenotype. MX69-induced cell death is indeed due to apoptosis. MX69-induced cell apoptosis and death are dependent on MDM2, p53, and XIAP expression. MX69 shows minimal inhibitory effect on normal human bone marrow in vitro.


Kinase Assay: MX69 is a novel, potent and selective MDM2/XIAP dual inhibitor that has the potential use for treatment of cancer. MX69 blocks the MDM2 protein-XIAP RNA interaction which leads to MDM2 degradation.


Cell Assay: The cytotoxic effect of leads on six ALL cell lines (EU-1, EU-3, EU-6, EU-8, SUP-B13, and UOC-B1) and six NB cell lines (NB-1691, NB-1643, SH-EP1, IMR-32, SK-NSH, and LA1-55N) is determined using the WST assay. Briefly, cells cultured in 96-well microtiter plates are treated with different concentrations of leads for a 20-hr period. WST (25 mg/well) is then added and incubation continued for an additional 4 hr, after which the optical density is read with a microplate reader.

In VivoMX69 has significant apoptotic and anti-proliferative effects on MDM2-expressing cancer cells in vivo. MX69 is well tolerated in animals due to the fact that normal cells/tissues express little or no MDM2. No evidence of toxicity after treatment with MX69 at the 100 mg/kg dose. MDM2-specific agent MX69 should not activate either on-target (e.g., p53 induction) or off-target signaling pathways in normal cells. Thus, specific MDM2 inhibitors such as MX69 may be excellent candidates for targeted therapy of refractory cancers expressing high levels of MDM2.
生物活性


Effect of leads on expression and function of p53 and XIAP following inhibition of MDM2. Cancer Cell. 2016 Oct 10;30(4):623-636.


Cytotoxic and apoptotic effects of leads on cancer and normal cells (A and B) WST assay for cytotoxic effect of MX69on ALL (A) and NB (B) cells as indicated. Cancer Cell. 2016 Oct 10;30(4):623-636.



Dependence of MX69-induced cell death on MDM2 and XIAP expression and p53 status (A) Comparison of MX69 IC50 values in MDM2 KO (sgMDM2) EU-1 and SH-EP1 cells in presence or absence of sip53. Cancer Cell. 2016 Oct 10;30(4):623-636.